Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine—Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation. Data S1: ejh70021-sup-0001-Supinfo. Figure S1: Treatment history and outcome of patients with extramedullary AML. Swimmer plot showing the timeline of prior therapies (left, in blue) and responses to azacitidine–venetoclax (right, in green) for each patient (n = 9). 7 + 3 = cytarabine for 7 days + anthracycline for 3 days (standard induction regimen); AZA, azacitidine; CPX-351, liposomal formulation of cytarabine and daunorubicin; CR, complete remission; FLAI, fludarabine, cytarabine (Ara-C), and idarubicin; HAM, high-dose cytarabine plus mitoxantrone; HSCT, hematopoietic stem cell transplantation; PR, partial response; REL, relapse; RT, radiotherapy. Green circles indicate patients alive at last follow-up, whereas green triangles indicate death. Asterisks (*) mark the presence of favorable-risk features (e.g., NPM1 mutation or CBFB-MYH11 translocation). Figure S2: Overall survival according to occurrence of favorable molecular marker among patients with AML with simultaneous medullary and extramedullary disease. Kaplan–Meier curve showing overall survival stratified by presence of favorable-risk markers (NPM1 mutation or CBFB-MYH11 translocation). Patients with favorable-risk features (n = 2, green line) had not reached median OS, whereas those without such markers (n = 4, blue line) had a median OS of 4.7 months (p = 0.049). mo, months. Figure S3: Duration of response (DoR) in responding patients. Kaplan–Meier curve showing the duration of response among the six patients who achieved either complete or partial remission following AZA-VEN therapy. The median DoR was 2.5 months (95% CI, 1.1–3.8). mo, months. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.